Navigation Links
Favrille Announces Resolution of Debt Obligations and Plans for Maximizing Assets
Date:7/7/2008

cility and other assets over the past few weeks," said John P. Longenecker, Ph.D., President and Chief Executive Officer of Favrille. "The future direction of the Company going forward remains uncertain but could include either a reorganization which might involve in-licensing of products contingent upon additional financing, a merger with another entity or liquidation of the Company either inside or outside of bankruptcy. We will continue to explore the relative benefits of all these options. The management and board of directors of Favrille remain committed to addressing these issues and maximizing the value of our assets as expeditiously as possible."

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Favrille's product candidates, proprietary technologies and research and clinical development programs. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to Favrille's ability to continue its operations, conserve cash or recognize value on our assets and additional risks discussed in Favrille's filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement. Favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements containe
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
2. Favrille CEO to Present at Bear Stearns Healthcare Conference
3. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
4. Favrille to Present at BIO InvestorForum
5. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
6. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
7. Favrille Announces $21.1 Million Registered Direct Offering
8. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
9. Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008
10. Favrille Reports First Quarter 2008 Financial Results
11. Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... forces worldwide rely on sophisticated equipment, trained personnel, ... public areas against terrorist attacks. A revolutionary new ... to make their job much easier. , The ... of Tel Aviv University ,s School of Chemistry ... by the Herzliya company Tracense, picks up the ...
(Date:7/24/2014)... to settle into equilibriuma state of unchanging balance ... of non-equilibrium conditions where new possibilities lie. Non-equilibrium ... such as temperature fluctuations, freezing and melting, or ... body temperature, airplanes to fly, and the Earth ... even though these conditions exist naturally and are ...
(Date:7/24/2014)... , July 24, 2014 SRI International has ... the National Institute of Allergy and Infectious Diseases (NIAID), ... preclinical development of potential therapies for HIV infection and ... treat HIV and AIDS and the complications and opportunistic ... for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... 24, 2014  Neogen Corporation (Nasdaq: NEOG ... its potential revenue from new rodenticide research are premature. ... analysts on July 22, 2014, Neogen,s CEO commented about ... research. "It was my intent Tuesday at ... of a new type of rodenticide, but certainly not ...
Breaking Biology Technology:Nano-sized chip 'sniffs out' explosives far better than trained dogs 2New approach to form non-equilibrium structures 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3Neogen comments on SenesTech 2
... 2009 ... ... 2009 -- IntertechPira has teamed up with Carbonfund.org to create a zero-carbon event. ... those emissions to make the event carbon neutral by supporting energy efficiency, renewable energy ...
... , , SAN DIEGO, CA, July 30, ... second quarter 2009 financial results on Tuesday, August 4, 2009 before the ... conference call with a live Internet broadcast that will provide a corporate ... day at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time). , ...
... , , ALPHARETTA, Ga., ... recently announced the appointment of Philip Vogt as Executive Vice ... brings more than thirty years of pharmaceutical experience and ... Prior to this role, Vogt served as President of Ethex ...
Cached Biology Technology:Biopolymers Symposium 2009 Teams with Carbonfund.org to Create a Zero-Carbon Event 2SENOMYX, INC. SECOND QUARTER 2009 EARNINGS CONFERENCE CALL SCHEDULED FOR AUGUST 4, 2009 2
(Date:7/24/2014)... animal species for food or commercial food sale, has ... the decline of many species of primates and other ... than half of the species being consumed are birds, ... not only the meat made available for sale but ... by hunters and brought to villages for consumption, we ...
(Date:7/24/2014)... Imagine a smog-free Los Angeles, where electric cars ply ... run on heat from beneath the earth, from howling ... new Stanford study finds that it is technically and ... one powered by clean, renewable energy. Published in ... sustainable, inexpensive and reliable energy supply in California that ...
(Date:7/24/2014)... team of researchers has developed a new nanoscale agent ... method for assessing the function and properties of the ... diagnosis and treatment of gut diseases. , ... syndrome and inflammatory bowel disease all occur in the ... patients with diseases such as diabetes and Parkinson,s. ...
Breaking Biology News(10 mins):Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4New imaging agent provides better picture of the gut 2
... Advanced Computing Center (TACC) at the University of Texas ... support a world-class supercomputer with comprehensive computing and visualization ... possible by a $27.5 million grant from the National ... the NSF "eXtreme Digital" (XD) program, an integrating system ...
... immobilize and devour amphibian prey many times their size. Now ... of Zoology, has discovered that they have an additional advantage ... adult counterparts, have a unique method for luring and feeding ... sirens who lured Ulysses, sailors to their demise, larvae have ...
... genetic variant may explain why some people with asthma do ... medicine for long-term asthma control. Researchers found that asthma patients ... only one-third as well to steroid inhalers as those with ... association study, funded by the National Heart, Lung, and Blood ...
Cached Biology News:Stampede charges computational science forward in tackling complex societal challenges 2Stampede charges computational science forward in tackling complex societal challenges 3Stampede charges computational science forward in tackling complex societal challenges 4Amphibians: Beware young beetles' deadly 'siren call' 2NIH-funded study connects gene variant to response to asthma drugs 2
... loxP-PGK-gb2-neo-loxP template is designed to allow ... cells. The loxP-PGK-gb2-neo-loxP template encodes ... a prokaryotic promoter (gb2) for expression ... a eukaryotic promoter (PGK) for expression ...
... depletion cocktail is tailored to ... from suspensions of rat spleen ... the StemSep (or compatible 0.5 ... system. The CD4+ T cell ...
Standard Fluka For microscopy (Hist.) redox indicator...
... The VSOS-4 Orbital Shaker is designed ... to provide a uniform motion that is both ... The VSOS-4 Orbital Shaker provides a smooth, quiet, ... for a wide range of laboratory applications such ...
Biology Products: